Related Experiment Video

Updated: Feb 14, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.2K

Efficacy of Low-Dose Fluconazole for Primary Prophylaxis of Invasive Candida Infections in Patients With Acute

Roghayeh Savary-Kouzehkonan1, Kourosh Sadeghi1, Soroush Rad2

  • 1Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Cancer Medicine
|March 28, 2025
PubMed
Abstract

Insights

Low-dose fluconazole effectively prevents Candida infections in acute leukemia patients, offering similar efficacy and safety to high-dose regimens. This approach is a viable alternative, though aspergillosis requires further attention.

Area of Science:

  • Oncology
  • Infectious Diseases
  • Clinical Pharmacology

Background:

  • Invasive fungal infections (IFIs) pose a significant risk to acute leukemia patients undergoing chemotherapy.
  • Fluconazole is a common prophylactic agent, but optimal dosing for acute leukemia patients remains unclear.
  • This study investigated low-dose fluconazole for primary prophylaxis against invasive Candida infections.

Purpose of the Study:

  • To evaluate the efficacy and safety of low-dose fluconazole compared to standard high-dose fluconazole for primary prophylaxis.
  • To assess the incidence of invasive Candida infections and colonization rates.
  • To monitor for adverse events and the occurrence of aspergillosis.

Main Methods:

  • A double-blind, randomized clinical trial was conducted.
  • 120 acute leukemia patients were randomized to receive either 150 mg/day (low-dose) or 400 mg/day (high-dose) fluconazole.
  • Primary outcomes included antifungal prophylaxis efficacy and safety profiles.

Main Results:

  • Overall Candida infection incidence was similar between low-dose and high-dose fluconazole groups (p=0.615).
  • Candida colonization was transiently higher in the low-dose group, particularly non-albicans species.
  • Aspergillosis incidence and adverse events were comparable between groups.

Conclusions:

  • Low-dose fluconazole is an effective and safe alternative for preventing Candida infections in acute leukemia patients.
  • The study underscores the need for targeted prophylaxis against emerging threats like aspergillosis.
  • Further research is recommended to optimize prophylaxis strategies for high-risk patient populations.
Keywords:
Candidaacute leukemiaantifungal prophylaxisfluconazolehematological malignancyinvasive fungal infection

More Related Videos

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients05:26

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Published on: March 1, 2024

2.1K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.8K

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
280
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.9K
Blind Procedures02:07

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
13.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.6K